

March 13, 2013

Mr. Aaron Muderick
Crazy Aaron Enterprises, Inc.
201 Sabine Ave
Narberth, PA 19072

Subject: 2013 Toxicological Risk Assessment¹ on New Components in Thinking Putty Products

Dear Mr. Muderick:


A Toxicological Risk Assessment was performed on the new components of the Crazy Aaron Enterprises, Inc. product line to determine whether they are safe to use, as supplied and in the toy product, or whether they constitute a risk to human health or the environment.

This assessment, based on 16CFR 1500.3(b)(5) and 16CFR 1500.39b(7) – (9), builds on previous safety assessments, which primarily focused on compliance with 67/548/EEC in the EU, and also addresses compliance with procedures set out in Module B of Annex II to Decision No. 768/2008/. Those previous reviews verified that the components in Thinking Putty should not cause damage to human health when used under normal or foreseen conditions. This current assessment¹ also finds that Crazy Aaron Enterprises' Thinking Putty, and its components, conform to all current toy regulations and also do not constitute a risk to human health or the environment. Thinking Putty is not classified as being toxic (acute), corrosive, irritating to the skin or eyes, nor as a strong sensitizer as defined in 16CFR 1500.3(b)(5) and 16CFR 1500.39b(7) – (9).

Exposure considerations were also re-evaluated. Dermal exposure will occur and is the primary route of exposure. Accidental ingestion is possible, although unlikely when used by people over the age of 3 (Magnetic Thinking Putty usage is limited to ages 8+ due to magnet safety considerations). Thinking Putty products, and their new components, were found to be safe for their intended use when age guidelines are followed in order to prevent choking on putty or the ingestion of magnets or magnet fragments.

Taking into account the above hazard and exposure assessments, Thinking Putty is safe for use as intended as a toy product and conforms to 16CFR 1500.3(b)(5) and 16CFR 1500.39b(7) – (9).

Signed by:


Mark E. Mayes
Managing Principal / Toxicologist
March 11, 2013

¹as defined in 16CFR 1500.3(b)(5) and 16CFR 1500.39b(7) – (9)